MRSN Stock: Mersana Therapeutics, Inc. Stock Price, Analysis & Insights
Get live mrsn stock price $27.43, comprehensive Mersana Therapeutics, Inc. stock analysis, charts, news, and expert forecast. Real-time mrsn stock data and investment insights.
Loading chart...
Company Overview
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
Company Information
- CEO
- Martin H. Huber
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 102
Contact Information
- Website
- https://www.mersana.com
- Address
- 840 Memorial Drive
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: 0.62) may provide portfolio stability
Business Model & Strategy
Mersana Therapeutics, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Martin H. Huber, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Mersana Therapeutics, Inc. competes in the Biotechnology within the broader Healthcare. With 136.9 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Mersana Therapeutics, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Mersana Therapeutics, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Mersana Therapeutics, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Mersana Therapeutics, Inc.
- ⚠Investors should consider how Mersana Therapeutics, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
136.89M
P/E Ratio
-1.85
Beta
0.62
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 136.89M market capitalization
- Trading Volume: 3.14M shares traded today
- Price Range: 52-week range of $5.21 - $70.72
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc. (MRSN) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 136.89M, the company represents a significant player in its market. The stock is currently trading at $27.43 with a positivedaily change of 209.24%.
The company's 102 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -1.85, beta of 0.62, and 52-week price range from $5.21 to $70.72when evaluating investment opportunities.
Why Invest in Mersana Therapeutics, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Martin H. Huber
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.